Intact Investment Management Inc. Bristol Myers Squibb CO Transaction History

Intact Investment Management Inc.

$2.63 Billion
Q4 2024

A detailed history of Intact Investment Management Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Intact Investment Management Inc. holds 55,800 shares of BMY stock, worth $3.11 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

55,800

Previous 304,400 81.67%

Holding current value

$3.11 Million

Previous $15.8 Million 79.96%

% of portfolio

0.12%

Previous 0.57%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$51.92 - $59.94 $12.9 Million - $14.9 Million	-248,600 Reduced 81.67%	55,800 $3.16 Million
Q3 2024 Oct 29, 2024	BUY	$39.66 - $51.75 $801,131 - $1.05 Million	20,200 Added 7.11%	304,400 $15.8 Million
Q2 2024 Jul 30, 2024	BUY	$40.25 - $52.99 $9.07 Million - $11.9 Million	225,400 Added 383.33%	284,200 $11.8 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $3.55 Million - $3.94 Million	-55,700 Reduced 48.65%	58,800 $3.76 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $4.9 Million - $5.55 Million	-74,500 Reduced 39.42%	114,500 $7.94 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $1.31 Million - $1.55 Million	-19,100 Reduced 9.18%	189,000 $13.6 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $52 - $30,736	400 Added 0.19%	208,100 $14.8 Million
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $1.27 Million - $1.4 Million	-17,500 Reduced 7.77%	207,700 $16 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $928,348 - $1.11 Million	-15,100 Reduced 6.28%	225,200 $16.4 Million
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $96,534 - $112,536	-1,800 Reduced 0.74%	240,300 $15 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $272,182 - $318,826	4,600 Added 1.94%	242,100 $14.3 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $3.31 Million - $3.72 Million	55,700 Added 30.64%	237,500 $15 Million
Q3 2020 Nov 12, 2020	BUY	$57.43 - $63.64 $2.85 Million - $3.16 Million	49,700 Added 37.62%	181,800 $11 Million
Q2 2020 Jul 29, 2020	BUY	$54.82 - $64.09 $2.52 Million - $2.95 Million	46,000 Added 53.43%	132,100 $7.76 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $1.54 Million - $2.24 Million	33,200 Added 62.76%	86,100 $4.79 Million
Q4 2019 Feb 18, 2020	BUY	$49.21 - $64.19 $2.6 Million - $3.4 Million	52,900 New	52,900 $3.39 Million
Q4 2019 Feb 12, 2020	SELL	$49.21 - $64.19 $2.44 Million - $3.18 Million	-49,500 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $213,850 - $253,550	-5,000 Reduced 9.17%	49,500 $2.51 Million
Q1 2019 May 10, 2019	SELL	$45.12 - $53.8 $1.21 Million - $1.44 Million	-26,800 Reduced 32.96%	54,500 $2.6 Million
Q4 2018 Jan 22, 2019	SELL	$48.76 - $63.23 $185,288 - $240,274	-3,800 Reduced 4.47%	81,300 $4.22 Million
Q3 2018 Oct 29, 2018	BUY	$55.19 - $62.25 $165,570 - $186,750	3,000 Added 3.65%	85,100 $5.28 Million
Q1 2018 May 08, 2018	BUY	$59.92 - $68.98 $4.51 Million - $5.19 Million	75,200 Added 1089.86%	82,100 $5.19 Million
Q3 2017 Oct 27, 2017	BUY	$55.23 - $63.74 $381,087 - $439,806	6,900	6,900 $440,000

Others Institutions Holding BMY

# of Institutions

2,749

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $119B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Intact Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Intact Investment Management Inc. with notifications on news.

Account

Intact Investment Management Inc. Bristol Myers Squibb CO Transaction History